^
    Back
    Association details:
    Biomarker:NR2F1 overexpression
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma

    Published date:
    01/15/2023
    Excerpt:
    High expression of NR2F1 promotes tumor survival and invasion in the presence of BRAFi + MEKi in vitro leading to tolerance to BRAFi + MEKi efficacy in vivo. Depletion of NR2F1 in YUMM1.7 allografts grown in aged mice improved response to the combination therapy.
    DOI:
    10.1158/1538-7445.AGCA22-A005
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma

    Published date:
    05/15/2020
    Excerpt:
    ...melanoma cells overexpressing NR2F1 were less sensitive to (CDK4/6i+MEKi) or BRAF and MEK inhibitors (BRAFi+MEKi) treatment in vitro and in vivo models, inhibiting apoptosis. Surprisingly, we did not find any evidence of decreased cell growth in our model.
    DOI:
    10.1158/1538-7445.AM2020-2986